BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.21), $0.04 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $6.8 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.